JPRN-UMIN000008538已完成4 期
Comparison of the long-term efficacy of silodosin and tamsulodin for the tratment of benign prostatic hyperplasia - Long-term effect of silodosin and tamsulodin
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 50years-old 至 90years-old（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •1) with prostatic cancer, prostatitis and urethral stricture, 2) with severe cardiac or cerebrovascular disorders, hepatic disorders, renal dysfunction, 4) on medication with anti-cholinergics, other alpha-AR antagonists, Beta-AR agonists or antagonists, or anti-androgen drugs during 1 month prior to the study.
研究者
相似试验
进行中（未招募）
1 期
A clinical study, which evaluates the effectiveness and the safety of a new medication for prostatic hyperplasia, silodosin, when administered under normal conditions of use in a wide European population.EUCTR2011-000045-20-ESRECORDATI S.p.A
进行中（未招募）
1 期
Effectiveness and safety of silodosin in the treatment of patients with benign prostatic hyperplasia.Benign prostatic hyperplasia.EUCTR2011-000045-20-RORECORDATI S.p.A
进行中（未招募）
不适用
Effectiveness and safety of silodosin in the treatment of LUTS in patients with benign prostatic hyperplasia: a European phase IV clinical study (the Silodosin in Real-life Evaluation study) - SIREBenign prostatic hyperplasia.MedDRA version: 13.1Level: PTClassification code 10004446Term: Benign prostatic hyperplasiaSystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2011-000045-20-HURECORDATI S.p.A1,000
进行中（未招募）
不适用
A clinical study, which evaluates the effectiveness and the safety of a new medication for prostatic hyperplasia, silodosin, when administered under normal conditions of use in a wide European population.EUCTR2011-000045-20-PTRECORDATI S.p.A1,000
进行中（未招募）
不适用
A clinical study, which evaluates the effectiveness and the safety of a new medication for prostatic hyperplasia, silodosin, when administered under normal conditions of use in a wide European population.EUCTR2011-000045-20-DERECORDATI S.p.A1,000